⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 16, 2024

Supplementary Fig. S2 from Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma

Uday P. Pratap Michael Tidwell Henriette U. Balinda Nicholas A. Clanton Xue Yang Suryavathi Viswanadhapalli Gangadhara R. Sareddy Dong Liang Huan Xie Yidong Chen Zhao Lai Rajeshwar R. Tekmal Stanton F. McHardy Andrew Brenner Ratna K. Vadlamudi

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

Supplementary Fig.S2 shows data shows specificity of CIDD-0149897 using ER beta KO cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pratap et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875237bb https://doi.org/10.1158/1535-7163.27036506

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig. S2 from Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma2024
2Supplementary Fig. S1 from Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma2024
3Supplementary Fig. S1 from Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma2024
4Supplementary Fig. S3 from Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma2024
5Supplementary Fig. S3 from Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma2024